The Lee and BDR decisions signal a shift in the landscape of compulsory licensing in India. This post examines the legal and policy developments leading to these outcomes, highlighting their implications for the Indian pharmaceutical industry.
Read more about Lee and BDR decision – the End of Compulsory Licenses?!Tag: Pharmaceutical patents
Government Bats for US trained Patent Examiners
The Indian government’s plan to engage US trained patent examiners has sparked debate over efficiency and policy direction in the patent office. This post analyses the benefits, concerns, and broader implications for India’s patent examination system.
Read more about Government Bats for US trained Patent ExaminersMerck v. Glenmark – A Bitter Battle of Pills
The Delhi High Court restrained Glenmark from manufacturing and marketing generic versions of Merck’s patented antidiabetic drugs. This case underscores key principles of Indian patent law and the balance between patent rights and public interest.
Read more about Merck v. Glenmark – A Bitter Battle of PillsCompulsory Licensing in India
This article analyses the evolution and practice of compulsory licensing in India, focusing on landmark cases and their effects on patent activity. It assesses whether compulsory licensing influences innovation and discusses the operational challenges within the Indian Patent Office.
Read more about Compulsory Licensing in IndiaPatents, Compulsory Licensing and Business Strategy
This article explores compulsory licensing in patents under Indian law, focusing on its impact on business strategies and public interest. Through case studies and legal analysis, the article highlights the importance of aligning patent management with India’s unique legal framework.
Read more about Patents, Compulsory Licensing and Business StrategyGilead, IPA, Natco & The Bells of Harmony
The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access to affordable medicines while balancing public health and patent rights.
Read more about Gilead, IPA, Natco & The Bells of HarmonyPfizer files for Patent on Known Substance
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether unpublished patent applications can render a substance as “known” and critiques the merging of novelty and subject matter analysis.
Read more about Pfizer files for Patent on Known SubstancePfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence of enhanced efficacy in pharmaceutical patent applications.
Read more about Pfizer falls prey to Section 3(d)Lee Pharma v. AstraZeneca- An unfinished Patent Story
This post examines the Lee Pharma v. AstraZeneca case on compulsory licensing under Indian patent law. The Controller’s decision sheds light on the standards for proving public need, affordable pricing, and working of patents in India.
Read more about Lee Pharma v. AstraZeneca- An unfinished Patent StoryIntellectual Property (IP) in India: A Decade of Progress Part 11
This post presents a statistical overview of pharmaceutical patents in India over the past decade, focusing on trends and key contributors. It objectively discusses the impact of legal changes and regulatory measures on patent filings in the pharmaceutical sector.
Read more about Intellectual Property (IP) in India: A Decade of Progress Part 11